関連する実験動画
Updated: May 12, 2026

07:29
Programmed Electrical Stimulation in Mice
Published on: May 27, 2010
SCN5A関連不律症候群におけるフレカニド作用のゲート依存メカニズム
P C Viswanathan1, C R Bezzina, A L George
1Department of Anesthesiology, Vanderbilt University, Nashville, Tennessee, USA.
Circulation
|September 6, 2001
まとめ
心臓ナトリウムチャネル (SCN5A) 変異は,LQT3およびブルガダ症候群を引き起こす. これらの変異における無活性化ゲーティングの欠陥は,フレカニドに対する感受性を高め,危険な不律を潜在的に引き起こします.
科学分野:
- 心血管遺伝学 心血管遺伝学
- 分子心臓病学 分子心臓病学
- 電気生理学 電気生理学
背景:
- 心臓ナトリウムチャネル遺伝子 (SCN5A) の変異は,LQT3およびブルガダ症候群に関連しています.
- ナトリウムチャネルを標的にする抗リズム薬は,これらの状態に対して反対の効果を持つことができます.
- フレカニドは,ナトリウムチャネルブロッカーであり,矛盾的にブルガダ症候群を悪化させ,LQT3患者にも同様の効果を引き起こす可能性があります.
研究 の 目的:
- LQT3およびブルガダ症候群におけるSCN5A不活性化ゲーティング欠陥が,フレカニドに対する前動脈異常感受性にどのように寄与するかを調査する.
- これらの遺伝性心疾患におけるフレカニド誘発性心律乱のメカニズム的根拠を解明する.
主な方法:
- 全細胞ナトリウム電流 (I(Na)) は,LQT3 (DeltaKPQ) と組み合わせたLQT3/ブルガダ (1795insD) 変異を表現するtsA-201細胞で測定されました.
- フレカニド (1ミクロモール/L) がI(Na) に与える効果と,不活性化後の回復を評価した.
- 変異型ナトリウムチャネルと野生型ナトリウムチャネルのフレカニドブロックと回復運動の比較.
主要な成果:
- DeltaKPQと1795insDの両方の変異は,不活性化ゲートを変化させ,フレカニドによって強化されたトニックI (Na) ブロックにつながりました.
- フレカイニドは,野生型 (16.8%) と比較して,1795insD (58.0%) とDeltaKPQ (39.4%) のチャネルにおいて,著しく大きなトニックブロックを引き起こした.
- 1795insD変異はまた,不活性化からの回復を遅らせ,中間の不活性化と使用依存のフレカインイドブロックの強化を示しています.
結論:
- LQT3とブルガダ症候群の変異に対するフレカインイド感受性の重要な要因として,2つの特定の無活性化ゲート欠陥 (閉じた状態の急速無活性化と中間無活性化) が特定されました.
- これらの発見は,SCN5A変異型に基づくフレカニドのプロアリズム的可能性を予測するためのメカニズム的根拠を提供します.
- これらのSCN5A不活性化ゲーティング欠陥を特定することは,これらのチャネル病変の患者に対するリスク層分化とパーソナライズされた治療戦略に役立ちます.
関連する概念動画
Voltage-gated Ion Channels
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
G-Protein Gated Ion Channels
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Sensory organs,...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

